192. コケイン症候群 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 4 / 薬物数 : 7 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 51
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
Prodarsan
DNage B.V.
2010 Phase 1/Phase 2 NCT01142154 United States;
Quercetin
The First Medical Center of PLA General Hospital
2019 Phase 0 ChiCTR1900026719 China;
Sirolimus
Premier Specialists, Australia
2016 Phase 2 NCT03016715 Australia;
Sirolimus,
Stanford University
2016 Phase 2 NCT02960997 United States;
Vehicle
Premier Specialists, Australia
2016 Phase 2 NCT03016715 Australia;
Stanford University
2016 Phase 2 NCT02960997 United States;
Vitamin C
The First Medical Center of PLA General Hospital
2019 Phase 0 ChiCTR1900026719 China;
DNage B.V.
2010 Phase 1/Phase 2 NCT01142154 United States;
Quercetin
The First Medical Center of PLA General Hospital
2019 Phase 0 ChiCTR1900026719 China;
Sirolimus
Premier Specialists, Australia
2016 Phase 2 NCT03016715 Australia;
Sirolimus,
Stanford University
2016 Phase 2 NCT02960997 United States;
Vehicle
Premier Specialists, Australia
2016 Phase 2 NCT03016715 Australia;
Stanford University
2016 Phase 2 NCT02960997 United States;
Vitamin C
The First Medical Center of PLA General Hospital
2019 Phase 0 ChiCTR1900026719 China;